[1]张志辉,束永兵.益气养血方联合促红素治疗糖尿病肾病腹膜透析患者肾性贫血临床观察[J].陕西中医,2024,(5):630-633.[doi:DOI:10.3969/j.issn.1000-7369.2024.05.012]
　ZHANG Zhihui,SHU Yongbing.Clinical efficacy of Yiqi Yangxue prescription combined with erythropoietin in the treatment of renal anemia in patients undergoing peritoneal dialysis for diabetic nephropathy[J].,2024,(5):630-633.[doi:DOI:10.3969/j.issn.1000-7369.2024.05.012]
点击复制

益气养血方联合促红素治疗糖尿病肾病腹膜透析患者肾性贫血临床观察
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年5期
页码:
630-633
栏目:
临床研究
出版日期:
2024-05-05

文章信息/Info

Title:
Clinical efficacy of Yiqi Yangxue prescription combined with erythropoietin in the treatment of renal anemia in patients undergoing peritoneal dialysis for diabetic nephropathy
作者:
张志辉; 束永兵
(六安市中医院肾病二科,安徽 六安 237000)
Author(s):
ZHANG Zhihui; SHU Yongbing
(Department 2 of Nephropathy,Lu'an Hospital of Traditional Chinese Medicine,Lu'an 237000,China)
关键词:
糖尿病肾病;  益气养血方;  促红素;  腹膜透析;  肾性贫血
Keywords:
Diabetic nephropathy;  Yiqi Yangxue prescription;  Erythropoietin;  Peritoneal dialysis;  Renal anemia
分类号:
R 587.2
DOI:
DOI:10.3969/j.issn.1000-7369.2024.05.012
文献标志码:
A
摘要:
目的:探究益气养血方联合促红素治疗糖尿病肾病腹膜透析(PD)患者肾性贫血的临床疗效。方法:选择糖尿病肾病PD合并肾性贫血患者60例,按照随机数字表法分为观察组和对照组各30例,对照组应用常规促红素治疗,观察组在对照组基础上联合益气养血方治疗,评估两组疗效,比较贫血指标、腹膜功能指标水平及不良反应。结果:治疗后,观察组中医证候积分明显低于对照组,且观察组临床疗效(90.00%)明显高于对照组(66.67%)(P<0.05); 治疗前两组贫血指标[血红蛋白(Hb)、血细胞比容(Hct)、红细胞计数(RBC)]比较无统计学差异(P>0.05),治疗后观察组Hb、Hct、RBC水平高于对照组(P<0.05); 治疗前,两组腹膜功能指标水平[PD血尿素清除指数(Kt/V)、透析液与血液中肌酐的浓度比值(D/Pcr)、PD超滤量(UF)]比较无统计学差异(P>0.05),治疗后,观察组Kt/V、D/Pcr、UF水平高于对照组(P<0.05); 观察组不良反应总发生率6.67%,对照组为23.33%,两者比较无统计学差异(P>0.05)。结论:益气养血方联合促红素治疗糖尿病肾病PD患者肾性贫血,可以有效缓解贫血症状,提高治疗疗效及改善贫血相关指标、腹膜功能,且不增加不良反应风险。
Abstract:
Objective:To investigate the clinical efficacy of Yiqi Yangxue prescription combined with erythropoietin in the treatment of renal anemia in patients undergoing peritoneal dialysis(PD)for diabetic nephropathy.Methods:A total of 60 patients with renal anemia who underwent PD for diabetic nephropathy were selected,according to random number table method divided into observation group and control group 30 cases each.The control group was treated with routine erythropoietin,while the observation group was treated with Yiqi Yangxue prescription on the basis of the control group.Efficacy in the two groups was evaluated.Anemia indicators,peritoneal function indicators and adverse reactions were compared between the groups.Results:TCM syndrome score after treatment,the observation group was obviously lower than the control group,and the clinical curative effect(90.00%)of the observation group was obviously higher than that of control group(66.67%)(P<0.05).Two groups before treatment of anemia indicators [hemoglobin(Hb),hematocrit(Hct),RBC count(RBC)] was no difference(P>0.05),the observation group after treatment of Hb,Hct,RBC level were higher than the control group(P<0.05).Before treatment,two groups of peritoneal function index level [PD(Kt/V),blood urea clearance index of dialysate and creatinine in the blood concentration ratio(D/Pcr),PD ultrafiltration(UF)] was no difference(P>0.05),after treatment,the observation group of Kt/V,D/Pcr,UF levels higher than the control group(P<0.05).Observation group of adverse reactions to the total incidence of 6.67%,the control group was 23.33%,which showed no difference(P>0.05).Conclusion:Applying Yiqi Yangxue prescription combined with erythropoietin to treat renal anemia in patients undergoing PD for diabetic nephropathy can effectively alleviate anemia symptoms,and improve the therapeutic effect,anemia related indicators and peritoneal function,without increasing the risk of adverse reactions.

参考文献/References:

[1] YI C,WANG X,YE H,et al.Patient-reported gastrointestinal symptoms in patients with peritoneal dialysis:The prevalence,influence factors and association with quality of life[J].BMC Nephrology,2022,23(1):1-8.
[2] 董晓,吴海珊,余学清,等.腹膜透析早期技术失败及其危险因素的研究进展[J].中华肾脏病杂志,2022,38(2):144-150.
[3] 成水芹,周婷婷,张志宏,等.罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J].肾脏病与透析肾移植杂志,2022,31(1):9-14.
[4] 杨德玉,顾谊铮,岑俊,等.自动化腹膜透析在腹膜透析患者中的疗效及对血清尿酸炎性因子的影响研究[J].山西医药杂志,2021,50(16):2392-2394.
[5] 王冰.高通量血液透析对终末期肾衰患者营养状况及肾性贫血状况的影响[J].陕西医学杂志,2019,48(6):766-769.
[6] 黄思梅,胡煜琳.罗沙司他与重组人促红素联合静脉铁剂治疗铁达标的维持性血液透析患者肾性贫血的疗效比较[J].中国临床医生杂志,2023,51(5):574-577.
[7] 王伟.血液红细胞参数检验在贫血鉴别诊断中的价值分析[J].中国实用医药,2021,16(9):83-85.
[8] 李现成,屈凯,王宇,等.中医药治疗腹膜透析肾性贫血新策略[J].陕西中医,2023,44(4):538-540,544.
[9] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860-866.
[10] 钟文娟,陈金英,周叶萍,等.小红细胞贫血因子和低血红蛋白密度在献血人群铁缺乏中的诊断价值[J].中华检验医学杂志,2023,46(3):304-309.
[11] 张逸馨,任桐.维持性腹膜透析患者应用低氧诱导因子-脯氨酰羟化酶抑制剂治疗肾性贫血的临床疗效分析[J].临床内科杂志,2023,40(1):60-61.
[12] 吴心虹,李泰标,廖秋菊,等.补肾养血祛浊方对肾性贫血大鼠血清及肾组织中性粒细胞明胶酶相关脂质运载蛋白的作用研究[J].陕西中医,2020,41(1):12-15.
[13] LI J,YU J,HUANG N,et al.Prevalence,risk factors and impact on outcomes of 30-day unexpected rehospitalization in incident peritoneal dialysis patients[J].BMC Nephrology,2021,22(1):4-8.
[14] 阮冬冬,袁军,曾毅,等.基于“肾生髓,髓生血”理论探讨肾性贫血的机制与治疗[J].世界中西医结合杂志,2021,16(10):1948-1951.
[15] 马妍,娄广亮,苏瑞芳,等.补肾健脾生血法治疗维持性血液透析肾性贫血疗效及血常规、肾功能指标变化研究[J].中华中医药学刊,2022,40(4):127-129.
[16] 刘正平,曹钋,钟剑,等.基于网络药理学探究黄芪-党参药对治疗糖尿病肾病的作用机制[J].中国医药导报,2021,18(34):121-125.
[17] 孟思璇,姚兴梅,吴歆叶,等.黄芪有效成分治疗糖尿病肾病的机制研究进展[J].中国医药导报,2023,20(4):60-63.
[18] 王欢,孙昊月,杨雪,等.罗沙司他治疗初始腹膜透析合并肾性贫血的生存率及预后影响因素研究[J].中国实用内科杂志,2023,43(2):148-154.
[19] 郑伟锋.益气养血汤对气血亏虚型椎基底动脉系统短暂性脑缺血性眩晕中医证候、动脉血流及血液流变学的影响[J].中华中医药学刊,2022,40(3):69-72.
[20] 张惠惺,侯怡飞,金珏,等.从现代医学的血液循环角度探析“营卫生会”理论[J].上海中医药杂志,2023,57(3):38-43.
[21] 范斌,刘荣奇,曹洋.清热除湿汤加减联合IPL治疗轻中度脾胃湿热型玫瑰痤疮疗效研究[J].中国美容医学,2023,32(3):116-119.
[22] 夏誉溦,蔡连香,张树成,等.养血补肾中药治疗肾虚型无排卵不孕症的临床疗效及其对卵巢、子宫动脉血流动力学参数的影响[J].中国中西医结合杂志,2004,24(4):299-302.
[23] 伍玉娟,王琳,史伟,等.健脾益气方改善腹膜透析患者营养不良、微炎症状态临床观察[J].亚太传统医药,2021,17(8):90-93.
[24] 汪舒云,谢曼丽,孙可向,等.参苓白术散对大肠癌移植瘤模型小鼠化学疗法后肠道黏膜屏障的影响[J].上海中医药杂志,2023,57(4):57-64.
[25] 郑丽,刘明,孙雪林.基于数据挖掘的中药治疗肾性贫血的用药规律研究[J].中国药房,2023,34(5):591-594,619.

相似文献/References:

[1]张华贞.复方黄芪汤加减联合骨化三醇治疗糖尿病肾病疗效及对患者血糖、肾功的影响*[J].陕西中医,2019,(6):767.
[2]程红卫,成晓萍.阎晓萍从脾论治糖尿病肾病经验总结*[J].陕西中医,2019,(6):790.
[3]黄聪丽,王治新△.益气滋肾活血通络方治疗早中期糖尿病肾病临床研究[J].陕西中医,2019,(10):1390.
　HUANG Congli,WANG Zhixin..Clinical efficacy analysis of Yiqi Zishen Huoxue Tongluo decoctionon early and medium stage of diabetic nephropathy[J].,2019,(5):1390.
[4]玉山江·艾克木,哈丽达·木沙△,地丽尼嘎尔.西红康联合还原型谷胱甘肽治疗2型糖尿病肾病Ⅲ期气阴两虚夹瘀证疗效及对患者微炎症状态、抗氧化的影响*[J].陕西中医,2020,(3):338.
　Yushanjiang·Aikemu,Halida·Musha,Dilinigaer..Efficacy of adjuvant therapy of Xihongkang on type 2 diabetic nephropathy Ⅲ phase with syndrome of Qiyin Liangxu Jiayu type and its effect on micro inflammation and antioxidant role[J].,2020,(5):338.
[5]马民凯,马红建,陈新苗.通络散结汤对3期糖尿病肾病患者GFR、UAER、β2-MG、Cys-C及微炎症状态的影响*[J].陕西中医,2020,(10):1432.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.025]
[6]田娟娟,陈 强,周欣欣,等.益气养阴活血法治疗糖尿病肾病理论探究*[J].陕西中医,2020,(12):1781.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.026]
[7]代广玉,修丽梅.糖尿病肾病中医辨证分型研究进展[J].陕西中医,2021,(1):131.[doi:DOI:10.3969/j.issn.1000-7369.2020.01.036]
[8]赵 亚,张勉之,樊威伟,等.国医大师张大宁治疗糖尿病肾病用药经验[J].陕西中医,2021,(6):773.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.025]
[9]张 蕊,王子承,蒋荣莉,等.防己黄芪汤加味治疗糖尿病肾病疗效及对患者糖脂代谢、氧化应激的影响[J].陕西中医,2021,(8):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
　ZHANG Rui,WANG Zicheng,JIANG Rongli,et al.Effect of Fangji Huangqi decoction on diabetic nephropathy and its influence on glucose and lipid metabolism and oxidative stress[J].,2021,(5):1049.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.015]
[10]方锦颖,王一冲,神原优滋(日本),等.基于网络药理学和分子对接探究肾康注射液治疗糖尿病肾病作用机制[J].陕西中医,2021,(12):1798.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.039]

备注/Memo

备注/Memo:
基金项目:安徽省重点研究与开发计划项目(202104J07020014)
更新日期/Last Update: 2024-05-09